Current concepts in the pathology and epigenetics of endometrial carcinoma.

[en] In the Western world, endometrial carcinoma is the most common malignant tumour of the female genital tract and is the fourth most common cancer in women. Two different clinicopathological subtypes are recognised: the oestrogen-related (type I, endometrioid) and the non-oestrogen related (type II, non-endometrioid). This article reviews the epidemiology, risk factors, genetic alterations during endometrial carcinogenesis, features of tumours and precursors and early detection of the disease. Insights into the epigenetic alterations, with emphasis on DNA methylation during endometrial carcinogenesis, and their diagnostic value are also provided.

Research Center/Unit :

Giga-Cancer - ULiège

Disciplines :

Oncology

Author, co-author :

Arafa, Mohammad; Department of Pathology, Faculty of Medicine, Mansoura University, Egypt

Somja, Joan ; Centre Hospitalier Universitaire de Liège - CHU > Anatomie pathologique

Dehan, Pierre ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Anatomie et cytologie pathologiques

Kridelka, Frédéric ; Centre Hospitalier Universitaire de Liège - CHU > Gynécologie-Obstétrique

Goffin, Frédéric ; Centre Hospitalier Universitaire de Liège - CHU > Gynécologie-Obstétrique CHR

Boniver, Jacques ; Centre Hospitalier Universitaire de Liège - CHU > Anatomie pathologique

Delvenne, Philippe ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Anatomie et cytologie pathologiques

Language :

English

Title :

Current concepts in the pathology and epigenetics of endometrial carcinoma.

Publication date :

2010

Journal title :

Pathology

ISSN :

0031-3025

eISSN :

1465-3931

Publisher :

Taylor & Francis, Abingdon, United Kingdom

Volume :

Issue :

Pages :

613-7

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 25 November 2010

Statistics

Number of views

137 (17 by ULiège)

Number of downloads

8 (3 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Strom BL, Schinnar R, Weber AL, et al. Case-control study of postmenopausal hormone replacement therapy and endometrial cancer. Am J Epidemiol 2006;164:775-86.
Persson I, Adami HO. Endometrial cancer. In: Adami HO, Hunter D, Trichopoulos D, editors. Textbook of Cancer Epidemiology. New York: Oxford University Press, 2002;359-77.
Parkin D, Whelan S, Ferlay J, Raymond L, Young J, editors. Cancer Incidence in Five Continents. Lyon, IARC, 1997.
Purdie DM, Green AC. Epidemiology of endometrial cancer. Best Pract Res Clin Obstet Gynaecol 2001;15:341-54.
Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983;150:10-7.
Ryan AJ, Susil B, Jobling TW, et al. Endometrial cancer. Cell Tissue Res 2005;322:53-61.
Hecht JL, Mutter GL. Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol 2006;24:4783-91.
Emons G, Fleckenstein G, Hinney B, Huschmand A, Heyl W. Hormonal interactions in endometrial cancer. Endocr Relat Cancer 2000;7:227-42.
Salvesen HB, MacDonald N, Ryan A, et al. Methylation of hMLH1 in a population-based series of endometrial carcinomas. Clin Cancer Res 2000;6:3607-13.
Ambros RA, Sherman ME, Zahn CM, et al. Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation. Hum Pathol 1995;26:1260-7.
Wheeler DT, Bell KA, Kurman RJ, et al. Minimal uterine serous carcinoma: diagnosis and clinicopathologic correlation. Am J Surg Pathol 2000;24:797-806.
Salvesen HB, Akslen LA. Molecular pathogenesis and prognostic factors in endometrial carcinoma. APMIS 2002;110:673-89.
Key T, Pike M. The dose-effect relationship between "unopposed" estrogen and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer 1988;57:205-12.
Munstedt K, Grant P, Woenckhaus J, et al. Cancer of the endometrium: current aspects of diagnostics and treatment. World J Surg Oncol 2004;2:24.
Grady D. Exercise, hormone therapy and lipoproteins in women. J Am Geriatr Soc 1996;44:331-2.
Sherman BM, Korenman SG. Measurement of serum LH, FSH, estradiol and progesterone in disorders of the human menstrual cycle: the inadequate luteal phase. J Clin Endocrinol Metab 1974;39:145-9.
Rogers WS, Gordon RE, Marsh MR. The incidence of malignancy in theca-cell tumors. Am J Obstet Gynecol 1952;64:1289-95.
Hartz AJ, Rupley DC, Rimm AA. The association of girth measurements with disease in 32, 856 women. Am J Epidemiol 1984;119:71-80.
Grodin JM, Siiteri PK, MacDonald PC. Source of estrogen production in postmenopausal women. J Clin Endocrinol Metab 1973;36:207-14.
Silverberg SG, Mutter GL, Kurman RJ, et al. Tumors of the uterine corpus: epithelial tumors and related lesions. In: Tavassoli FA, Devilee P, editors. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. World Health Organization Classification of Tumours. Lyon: IARC Press, 2003;221-32.
Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients. Cancer 1985;56:403-12.
McCluggage WG. My approach to the interpretation of endometrial biopsies and curettings. J Clin Pathol 2006;59:801-12.
Baak JP, Mutter GL. EIN and WHO94. J Clin Pathol 2005;58:1-6.
Lacey JV Jr, Mutter GL, Nucci MR, et al. Risk of subsequent endometrial carcinoma associated with endometrial intraepithelial neoplasia classification of endometrial biopsies. Cancer 2008;113:2073-81.
Sherman ME, Bittermann P, Rosenschein NB, et al. A morphologically diverse neoplasm with unifying clinicopathological features. Am J Surg Pathol 1992;16; 600-10.
Fadare O, Zheng W. Endometrial Glandular Dysplasia (EmGD): morphologically and biologically distinctive putative precursor lesions of Type II endometrial cancers. Diagn Pathol 2008;3:6.
Matias-Guiu X, Catasus L, Bussaglia E, et al. Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol 2001;32:569-77.
Prat J, Gallardo A, Cuatrecasas M, et al. Endometrial carcinoma: pathology and genetics. Pathology 2007;39:72-87.
Esteller M. Dormant hypermethylated tumour suppressor genes: questions and answers. J Pathol 2005;205:172-80.
Risinger JI, Maxwell GL, Berchuck A, et al. Promoter hypermethylation as an epigenetic component in Type I and Type II endometrial cancers. Ann N Y Acad Sci 2003;983:208-12.
Zhou XC, Dowdy SC, Podratz KC, et al. Epigenetic considerations for endometrial cancer prevention, diagnosis and treatment. Gynecol Oncol 2007;107:143-53.
Liao X, Siu MK, Chan KY, et al. Hypermethylation of RAS effector related genes and DNA methyltransferase 1 expression in endometrial carcinogenesis. Int J Cancer 2008;123:296-302.
Herman JG, Umar A, Polyak K, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA 1998;95:6870-5.
Esteller M. Epigenetic lesions causing genetic lesions in human cancer: promoter hypermethylation of DNA repair genes. Eur J Cancer 2000;36:2294-300.
Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-54.
Furlan D, Carnevali I, Marcomini B, et al. The high frequency of de novo promoter methylation in synchronous primary endometrial and ovarian carcinomas. Clin Cancer Res 2006;12:3329-36.
Xiong Y, Dowdy SC, Gonzalez Bosquet J, et al. Epigenetic-mediated upregulation of progesterone receptor B gene in endometrial cancer cell lines. Gynecol Oncol 2005;99:135-41.
Li R, Saito T, Tanaka R, et al. Hypermethylation in promoter region of retinoic acid receptor-beta gene and immunohistochemical findings on retinoic acid receptors in carcinogenesis of endometrium. Cancer Lett 2005;219:33-40.
Kang S, Kim JW, Kang GH, et al. Comparison of DNA hypermethylation patterns in different types of uterine cancer: cervical squamous cell carcinoma, cervical adenocarcinoma and endometrial adenocarcinoma. Int J Cancer 2006;118:2168-71.
Arafa M, Kridelka F, Mathias V, et al. High frequency of RASSF1A and RARb2 gene promoter methylation in morphologically normal endometrium adjacent to endometrioid adenocarcinoma. Histopathology 2008;53:525-32.
Pallares J, Velasco A, Eritja N, et al. Promoter hypermethylation and reduced expression of RASSF1A are frequent molecular alterations of endometrial carcinoma. Mod Pathol 2008;21:691-9.
Pizzi S, Azzoni C, Bottarelli L, et al. RASSF1A promoter methylation and 3p21.3 loss of heterozygosity are features of foregut, but not midgut and hindgut, malignant endocrine tumours. J Pathol 2005;206:409-16.
Youssef EM, Lotan D, Issa JP, et al. Hypermethylation of the retinoic acid receptor-beta (2) gene in head and neck carcinogenesis. Clin Cancer Res 2004;10:1733-42.
Kang S, Lee JM, Jeon ES, et al. RASSF1A hypermethylation and its inverse correlation with BRAF and/or KRAS mutations in MSI-associated endometrial carcinoma. Int J Cancer 2006;119:1316-21.
Cheung AN. Molecular targets in gynaecological cancers. Pathology 2007;39:26-45.
Kanaya T, Kyo S, Maida Y, et al. Frequent hypermethylation of MLH1 promoter in normal endometrium of patients with endometrial cancers. Oncogene 2003;22:2352-60.
Smith RA, Cokkinides V, von Eschenbach AC, et al. American Cancer Society guidelines for the early detection of cancer. CA Cancer J Clin 2002;52:8-22.
Simsir A, Hwang S, Cangiarella J, et al. Glandular cell atypia on Papanicolaou smears: interobserver variability in the diagnosis and prediction of cell of origin. Cancer 2003;99:323-30.
Gu M, Shi W, Barakat RR, et al. Pap smears in women with endometrial carcinoma. Acta Cytol 2001;45:555-60.
DuBeshter B, Deuel C, Gillis S, et al. Endometrial cancer: the potential role of cervical cytology in current surgical staging. Obstet Gynecol 2003;101:445-50.
Brown AK, Gillis S, Deuel C, et al. Abnormal cervical cytology: a risk factor for endometrial cancer recurrence. Int J Gynecol Cancer 2005;15:517-22.
Gupta JK, Chien PF, Voit D, et al. Ultrasonographic endometrial thickness for diagnosing endometrial pathology in women with postmenopausal bleeding: a meta-analysis. Acta Obstet Gynecol Scand 2002;81:799-816.
Taylor PJ, Gomel V. Endometrial ablation: indications and preliminary diagnostic hysteroscopy. Baillière's Clin Obstet Gynaecol 1995;9:251-60.
Papaefthimiou M, Symiakaki H, Mentzelopoulou P, et al. The role of liquid-based cytology associated with curettage in the investigation of endometrial lesions from postmenopausal women. Cytopathology 2005;16:32-9.
Bradley WH, Boente MP, Brooker D, et al. Hysteroscopy and cytology in endometrial cancer. Obstet Gynecol 2004;104:1030-3.
Lerner JP, Timor-Tritsch IE, Monteagudo A. Use of transvaginal sonography in the evaluation of endometrial hyperplasia and carcinoma. Obstet Gynecol Surv 1996;51:718-25.
Teefey SA, Stahl JA, Middleton WD, et al. Local staging of endometrial carcinoma: Comparison of transvaginal and intraoperative sonography and gross visual inspection. AJR 1996;166:547-52.
Bonilla-Musoles F, Raga F, Osborne NG, et al. Three dimensional hysterosonography for the study of endometrial tumors: Comparison with conventional transvaginal sonography, hysterosalpingography and hysteroscopy. Gynecol Oncol 1997;65:245-52.
Turnbull LW, Jumaa A, Bowsley SJ, et al. Magnetic resonance imaging of the uterus after endometrial resection. Br J Obstet Gynaecol 1997;104:934-8.
Lentz SS. Endometrial carcinoma diagnosed by positron emission tomography: a case report. Gynecol Oncol 2002;86:223-4.
Brosens JJ. Uterine junctional zone: function and disease. Lancet 1995;346:558-60.
Fiegl H, Gattringer C, Widschwendter A, et al. Methylated DNA collected by tampons-A new tool to detect endometrial cancer. Cancer Epidemiol Biomarkers Prev 2004;13:882-8.
Mutter GL, Lin MC, Fitzgerald JT, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 2000;92:924-30.
Lacey JV Jr, Ioffe OB, Ronnett BM, et al. Endometrial carcinoma risk among women diagnosed with endometrial hyperplasia: the 34-year experience in a large health plan. Br J Cancer 2008;98:45-53.
Lin MC, Burkholder KA, Viswanathan AN, et al. Involution of latent endometrial precancers by hormonal and nonhormonal mechanisms. Cancer 2009;115:2111-8.